U. M. Zanger

Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation.

U. Meyer, F. Gonzalez, T. Aoyama, 1990, The Journal of biological chemistry.

Truncated human P450 2D6: expression in Escherichia coli, Ni(2+)-chelate affinity purification, and characterization of solubility and aggregation.

U. Meyer, A. Kempf, U. M. Zanger, 1995, Archives of biochemistry and biophysics.

Extent and character of phenobarbital-mediated changes in gene expression in the liver.

F. Frueh, U. Meyer, U. M. Zanger, 1997, Molecular pharmacology.

Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

H. Hauri, U. Meyer, U. Zanger, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Molecular mechanisms of genetic polymorphisms of drug metabolism.

U. Meyer, U. Zanger, U A Meyer, 1997, Annual review of pharmacology and toxicology.

Nomenclature for human CYP2D6 alleles.

M. Ingelman-Sundberg, V. Steen, J. Brockmöller, 1996, Pharmacogenetics.

Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P‐450IID1

U. Meyer, A. Rane, D. Spalding, 1990, Clinical pharmacology and therapy.